

Our ref: IG/FOI/FOI.001.26

14 January 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 2 January 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

Could you please let me know which active primary care rebate schemes your organisation are currently signed up to?

Could you please provide the start and end dates of the contracts.

Powys Response:

Please see the table below for Powys Teaching Health Board's (PTHB) current primary care rebate schemes:

Please note: The below rebates are negotiated and hosted nationally by NHS Wales Shared Services Partnership (NWSSP), and they will be the same for all health boards:

Rebate	Company	Start date	End date
Abtard	Ethypharm UK Ltd	Oct-2015	Not specified
Accu-Chek instant	Roche Diagnostics Ltd	Oct-2024	Jul-2026
Accu-Chek Performa	Roche Diagnostics Ltd	Oct-2024	Jul-2026

Adcal D3	Kyowa Kirin International UK NewCo Ltd	Jan-2016	Not specified
Aimovig	Novartis Pharmaceuticals Ltd	Apr-2021	Sep-2027
Ajovy	Teva UK Ltd	Apr-2025	Mar-2027
Altrajuce	Nualtra LTD	Oct-2024	Sep-2026
Aproderm	Fontus Health	Oct-2023	Sep-2026
Aproderm Barrier Cream	Fontus Health	Oct-2023	Sep-2026
Aquacel	Conva Tec Ltd	Jul-2023	Dec-2025
Ationdo	Grunenthal (UK) Ltd	Jul-2025	Jun-2028
BD Viva Needles 2	Embecta U.K. Limited	Apr-2025	Mar-2027
Bupeaze	Dr Reddys Laboratories (UK) Ltd	Oct-2022	Sep-2026
Buvidal	Camurus	Jul-2024	Jun-2026
Cetraben 3	Thornton & Ross	Jan-2025	Dec-2025
Clenil Modulite	Chiesi Ltd	Jan-2024	Dec-2025
Codimaz	Scope Ophthalmics Ltd	Jul-2023	Jun-2026
Cosentyx	Novartis Pharmaceuticals Ltd	Apr-2023	Sep-2027
Cynril	Fontus Health	Jan-2024	Dec-2026
Dimaz	Scope Ophthalmics Ltd	Jul-2023	Jun-2026
Emeside	Fontus Health	Jan-2025	Dec-2026
Emgality	Organon Pharma (UK) Ltd	Jul-2024	Not specified
Ensure Compact	Abbott Laboratories	Jul-2025	Dec-2026
Epesri	Strides Pharma UK Ltd	Apr-2022	Mar-2026
Epidyolex	Jazz Pharmaceuticals Operations UK Ltd	Oct-2024	Sep-2027
Espranor	Ethypharm UK Ltd	Jan-2022	Dec-2026
Estraderm	Norgine Pharmaceutical Limited	Jan-2025	Dec-2025
Evrenzo	Astellas Pharma Europe Ltd	Jan-2023	Dec-2025
Fencino 2	Luye Pharma	Jan-2023	Not specified

Fixkoh - 2	Thornton & Ross	Apr-2025	Mar-2026
Foodlink	Nualtra LTD	Oct-2024	Sep-2026
Fostair NEXThaler	Chiesi Ltd	Jan-2024	Dec-2025
Fostair pMDI	Chiesi Ltd	Apr-2024	Mar-2026
Freestyle Libre 2	Abbott Laboratories Ltd	Jul-2025	Not specified
Fycompa	Eisai Limited	Apr-2023	Mar-2026
Glucophage SR	Merck Serono Limited	Jan-2022	Not specified
Hylo Fresh	Scope Ophthalmics Ltd	Apr-2022	Mar-2026
Hylo Night Ointment	Scope Ophthalmics Ltd	Apr-2022	Mar-2026
Invokana	A.Menarini Farmaceutica Internazionale SRL	Oct-2024	Sep-2026
Jyseleca	Alfasigma	Oct-2024	Mar-2026
Leqvio	Novartis Pharmaceuticals Ltd	Jan-2022	Sep-2027
Luventa	Fontus Health	Oct-2015	Not specified
Monopost	Thea Pharmaceuticals	Jul-2025	Jun-2027
Mounjaro	Eli Lilly and Company Limited	Oct-2025	Aug-2028
NILEMDO & NUSTENDI	Daiichi Sankyo UK Ltd	Apr-2021	Mar-2031
Orobalin	Northumbria Pharma Ltd	Jan-2025	Not specified
Otezla	Amgen	Jan-2023	Dec-2025
Oxeltra	Wockhardt UK Ltd	Apr-2025	Mar-2027
Physeptone	Ethypharm UK Ltd	Oct-2021	Sep-2026
Pipexus	Ethypharm UK Ltd	Jul-2018	Not specified
Praluent	Aventis Pharma Limited T/A Sanofi	Jan-2025	Dec-2025
Prostap DCS	Takeda	Apr-2017	Jun-2026
Repatha	Amgen	Jul-2016	Not specified
Resource Thicken Up Clear	Nestle UK Ltd	Jul-2025	Jun-2027
Revolade	Novartis Pharmaceuticals Ltd	Jan-2022	Sep-2027

Saxenda	Novo Nordisk	Jan-2021	Not specified
Sirdupla	Viartis UK Healthcare Limited	Apr-2025	Mar-2026
Slentyto	Flynn Pharma	Jan-2025	Mar-2027
Sotyktu	Bristol-Myers Squibb Pharmaceuticals Limited	Jan-2024	Dec-2026
Sprycel (Dasatinib)	Bristol-Myers Squibb Pharmaceuticals Limited	Jul-2018	Not specified
Staladex	Aspire Pharma	Jan-2025	Dec-2026
Strivit-D3	Strides Pharma UK Ltd	Jul-2023	Mar-2026
Tasigna	Novartis Pharmaceuticals Ltd	Jul-2022	Sep-2027
Tolthen XL	Fontus Health	Jan-2024	Dec-2026
Viscotears	Bausch & Lomb UK Ltd	Jul-2025	Jun-2027
Vizidor	Bausch & Lomb UK Ltd	Jul-2025	Jun-2027
Vliwasorb Pro	Lohmann & Rauscher	Jul-2025	Jun-2026
WaveSense JAZZ	AgaMatrix Europe Ltd	Oct-2024	Jul-2026
Wegovy FlexTouch	Novo Nordisk	Oct-2023	Not specified
Xaggitin	Ethypharm UK Ltd	Apr-2017	Not specified
Xailin	VISUfarma BV	Jul-2025	Jun-2026
XGEVA	Amgen	Jan-2025	Dec-2027
Xolair	Novartis Pharmaceuticals Ltd	Oct-2024	Sep-2027
Zaluron XL	Fontus Health	Oct-2015	Not specified
Zaponex	Leyden Delta	Jul-2023	Jun-2026
Zeposia	Bristol-Myers Squibb Pharmaceuticals Limited	Jan-2024	Dec-2026

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House,
Churchill Way, Cardiff, CF10 2HH.
Telephone: 0330 414 6421
Complaints Portal: www.ico.org.uk/foicomplaints
Web site: <https://ico.org.uk/>


Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.